SCHEMBL24514747

SCHEMBL24514747

O=C(CCCC[C@@H]1SC[C@@H]2NC(=O)N[C@@H]21)NCCOCCOCCOCCOCCOCCO

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
F2 P00734 1/20 0.69
PRSS1 P07477 1/20 0.69
PRSS2 P07478 1/20 0.69
PRSS3 P35030 1/20 0.69
TPSAB1 Q15661 1/20 0.69
PKM P14618 3/20 0.67
FOLH1 Q04609 4/20 0.65
TDP1 Q9NUW8 5/20 0.62
MEN1 O00255 1/20 0.58
ABL1 P00519 1/20 0.58
LMNA P02545 1/20 0.58
IDE P14735 1/20 0.58
MAPK1 P28482 1/20 0.58
KMT2A Q03164 1/20 0.58
RIN1 Q13671 1/20 0.58
L3MBTL1 Q9Y468 1/20 0.58
CA12 O43570 2/20 0.57
CA1 P00915 2/20 0.57
CA2 P00918 2/20 0.57
CA9 Q16790 2/20 0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22767679 1.00 F2 (0.69) F2PRSS1PRSS2PRSS3TPSAB1
SCHEMBL31578516 1.00 F2 (0.69) F2PRSS1PRSS2PRSS3TPSAB1
SCHEMBL30735826 1.00 F2 (0.69) F2PRSS1PRSS2PRSS3TPSAB1
SCHEMBL29485943 1.00 F2 (0.69) F2PRSS1PRSS2PRSS3TPSAB1
SCHEMBL24767163 1.00 F2 (0.69) F2PRSS1PRSS2PRSS3TPSAB1
SCHEMBL18549029 1.00 F2 (0.69) F2PRSS1PRSS2PRSS3TPSAB1
SCHEMBL31479957 1.00 F2 (0.69) F2PRSS1PRSS2PRSS3TPSAB1
SCHEMBL18550538 1.00 F2 (0.69) F2PRSS1PRSS2PRSS3TPSAB1
SCHEMBL3498955 0.99 F2 (0.67) F2PRSS1PRSS2PRSS3TPSAB1
SCHEMBL24766888 0.99 F2 (0.67) F2PRSS1PRSS2PRSS3TPSAB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260110690-A1 PROBE AND METHODS FOR IDENTIFYING HOST CELL PROTEIN IMPURITIES REGENERON PHARMACEUTICALS, INC. 2026-04-23 US disclosed
US-12540945-B2 Probe and method for identifying host cell protein impurities REGENERON PHARMACEUTICALS, INC. (US) 2026-02-03 US disclosed
US-12403144-B2 HECT E3 ligase inhibitors and uses thereof IFOM —FONDAZIONE ISTITUTO FIRC DI ONCOLOGIA MOLECOLARE (IT) 2025-09-02 US disclosed
EP-3976185-B1 HECT E3 LIGASE INHIBITORS AND USES THEREOF IFOM ST FONDAZIONE DI ONCOLOGIA MOLECOLARE ETS (IT) 2024-02-14 EP disclosed
US-20230184678-A1 METHODS FOR LOADING AND DATA ACQUISITION QUANTUM SI INC (US) 2023-06-15 US disclosed
US-20230083288-A1 PROBE AND METHOD FOR IDENTIFYING HOST CELL PROTEIN IMPURITIES REGENERON PHARMACEUTICALS, INC. 2023-03-16 US disclosed
US-20220339163-A1 HECT E3 LIGASE INHIBITORS AND USES THEREOF IFOM - FONDAZIONE ISTITUTO FIRC DI ONCOLOGIA MOLECOLARE (IT) 2022-10-27 US disclosed
US-20220187205-A1 SYSTEMS AND METHODS FOR CHIP REGENERATION QUANTUM SI INC (US) 2022-06-16 US disclosed
EP-3976185-A1 HECT E3 LIGASE INHIBITORS AND USES THEREOF IFOM - Fondazione Istituto FIRC di Oncologia Molecolare (IT) 2022-04-06 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220339163-A1 HECT E3 LIGASE INHIBITORS AND USES THEREOF NEDD4, ITCH, UBE3A F2 4877/4885PRSS1 2721/4885PRSS2 3809/4885
US-12403144-B2 HECT E3 ligase inhibitors and uses thereof NEDD4, ITCH, UBE3A F2 4877/4885PRSS1 2721/4885PRSS2 3809/4885
US-20260110690-A1 PROBE AND METHODS FOR IDENTIFYING HOST CELL PROTEIN IMPURITIES BTD, LIPC, LPL F2 3773/4885PRSS1 1418/4885PRSS2 1093/4885
US-12540945-B2 Probe and method for identifying host cell protein impurities BTD, LPL, LYPLA2 F2 4087/4885PRSS1 1597/4885PRSS2 1637/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.